Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

Ronan Flippot; Tuğçe Telli; Maud Velev; Aude Fléchon; Manon De Vries-Brilland; L. Turpin; Andries M. Bergman; Fabio Turco; Hakim Mahammedi; Wolfgang P. Fendler; Anne‐Laure Giraudet; Quentin Josset; Françoise Montravers; Wouter V. Vogel; Silke Gillessen; Simona Berardi Vilei; Ken Herrmann; David Kryza; Gaetano Paone; Boris Hadaschik; C. Merlin; Pierre-Alban Dufour; Alice Bernard‐Tessier; Natacha Naoun; Anna Patrikidou; Camilo Garcia; Stéphanie Foulon; Arnaud Pagès; Karim Fizazi

doi:10.1016/j.euo.2024.03.013

Abstract

Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor and docetaxel, but there are limited data regarding Lu-PSMA activity after cabazitaxel.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Flippot et al. (2024) studied this question.

synapsesocial.com/papers/68e6dc24b6db6435876584c0 https://doi.org/10.1016/j.euo.2024.03.013

View Full Paper

Ask AI

Bookmark

Share

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

Abstract

Discussion

Cite This Study

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Urology Oncology

Keep reading

More related papers

More from European Urology Oncology